Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Has Consensus Target Price of $75.44

Key Points

• Analyst sentiment is moderately bullish: Enliven Therapeutics has a consensus “Moderate Buy” rating from 12 analysts, with 10 buys and two sells. The average 12-month price target is $75.44, versus a recent share price of $44.78.
• Recent earnings fell short of expectations: The company reported a quarterly loss of $0.49 per share, missing the consensus estimate of a $0.39 loss; analysts expect a full-year loss of approximately $1.79 per share.
• Insiders have been selling while institutions hold significant stakes: Insiders sold roughly $11.1 million of shares over the past 90 days, while institutional investors and hedge funds own 95.08% of the stock.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has received an average rating of "Moderate Buy" from the twelve research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $75.44.

Several research analysts have recently weighed in on ELVN shares. Wall Street Zen downgraded shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Thursday, October 15th. Barclays started coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They set an "overweight" rating and a $78.00 price target on the stock. Guggenheim reiterated a "buy" rating on shares of Enliven Therapeutics in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics in a research report on Thursday, October 1st. They issued an "overweight" rating and a $75.00 price objective for the company.

Enliven Therapeutics Stock Performance

ELVN stock opened at $44.78 on Thursday. The stock has a 50-day simple moving average of $49.28 and a 200-day simple moving average of $42.38. The firm has a market cap of $3.28 billion, a P/E ratio of -26.81 and a beta of 0.24. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, equities research analysts predict that Enliven Therapeutics will post -1.79 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the business's stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company's stock, valued at $606,710. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 189,849 shares of company stock valued at $11,054,870. 3.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics during the second quarter worth approximately $221,255,000. First Light Asset Management LLC raised its holdings in Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock valued at $69,058,000 after acquiring an additional 1,158,883 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company's stock valued at $52,898,000 after acquiring an additional 847,399 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in Enliven Therapeutics by 3.5% during the 1st quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company's stock valued at $32,399,000 after acquiring an additional 28,095 shares during the last quarter. Finally, Siren L.L.C. bought a new position in Enliven Therapeutics during the 1st quarter valued at $29,252,000. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.